HARNESSING IMMUNE CELLS AGAINST BRAIN CANCER
The Australian Government has announced successful applicants for the Priority-driven Collaborative Cancer Research Scheme which aims to improve outcomes for patients affected by the disease.
Among the Institute scientists to receive support was Dr Misty Jenkins whose laboratory is focussed on designing new immunotherapies, an innovative treatment that redirects a patient’s own immune cells to kill cancer.
Dr Jenkins said she was grateful to receive funding from Cancer Australia for research to find new and improved immunotherapy treatments for childhood brain cancer.
|